{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:35:07Z","timestamp":1762508107721,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.hoc.2020.03.001","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T08:07:53Z","timestamp":1588666073000},"page":"785-794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of Histologic Transformation"],"prefix":"10.1016","volume":"34","author":[{"given":"Carla","family":"Casulo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.hoc.2020.03.001_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016\u00a0US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CACancer J Clin"},{"key":"10.1016\/j.hoc.2020.03.001_bib2","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.hoc.2020.03.001_bib3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.03.001_bib4","first-page":"e359","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"LancetHaematol"},{"key":"10.1016\/j.hoc.2020.03.001_bib5","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J\u00a0ClinOncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib6","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J\u00a0ClinOncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib7","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J\u00a0ClinOncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib8","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J\u00a0ClinOncol"},{"issue":"22","key":"10.1016\/j.hoc.2020.03.001_bib9","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood.V114.22.2698.2698","article-title":"Risk Factors for Early Transformation of Follicular Lymphoma (FL): Report From the National LymphoCare Study (NLCS)","volume":"114","author":"Wagner-Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.03.001_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO;2-M","article-title":"An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute","volume":"52","author":"Garvin","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2020.03.001_bib11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/annonc\/mds433","article-title":"Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy","volume":"24","author":"Bains","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":"Incidence, risk factors and outcome of histological transformation in follicular lymphoma","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.03.001_bib13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group","volume":"178","author":"Alonso-Alvarez","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.03.001_bib14","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J\u00a0ClinOncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.03.001_bib16","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J\u00a0ClinOncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib17","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2020.03.001_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma","volume":"36","author":"Luminari","year":"2018","journal-title":"J\u00a0ClinOncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib19","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2020.03.001_bib20","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J\u00a0ClinOncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib21","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","article-title":"Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database","volume":"30","author":"Solal-Celigny","year":"2012","journal-title":"J\u00a0ClinOncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib22","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomasdagger","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib23","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma","volume":"23","author":"Schoder","year":"2005","journal-title":"J\u00a0ClinOncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib24","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/annonc\/mdp030","article-title":"High SUV uptake on FDG-PET\/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET\/CT staging in lymphoma","volume":"20","author":"Ngeow","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib26","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.1995.13.7.1726","article-title":"Long-term survival after histologic transformation of low-grade follicular lymphoma","volume":"13","author":"Yuen","year":"1995","journal-title":"J\u00a0ClinOncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib27","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","article-title":"Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy","volume":"22","author":"Advani","year":"2004","journal-title":"J\u00a0ClinOncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12570","article-title":"Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database","volume":"163","author":"Ban-Hoefen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.03.001_bib29","first-page":"1805","article-title":"Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013","volume":"58","author":"Gleeson","year":"2017","journal-title":"LeukLymphoma"},{"key":"10.1016\/j.hoc.2020.03.001_bib30","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.2019000858","article-title":"Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.03.001_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","article-title":"Transformed follicular non-Hodgkin lymphoma","volume":"125","author":"Casulo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.03.001_bib32","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.2012.44.0693","article-title":"Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group","volume":"319","author":"Villa","year":"2013","journal-title":"J\u00a0ClinOncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/annonc\/mdu537","article-title":"Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation","volume":"2","author":"Madsen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2020.03.001_bib34","first-page":"1625","article-title":"High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma","volume":"50","author":"Smith","year":"2009","journal-title":"LeukLymphoma"},{"key":"10.1016\/j.hoc.2020.03.001_bib35","first-page":"406","article-title":"Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation","volume":"126","author":"Reddy","year":"2012","journal-title":"Clin\u00a0Lymphoma\u00a0Myeloma Leuk"},{"key":"10.1016\/j.hoc.2020.03.001_bib36","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtageneciloluecel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"26","author":"Neelpau","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.03.001_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisangenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.03.001_bib38","first-page":"357a","article-title":"Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmunotherapy with tositumomab and iodine I 131 tositumomab (Bexxar)","volume":"100","author":"Zelenetz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.03.001_bib39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2011.08781.x","article-title":"The differential effect of lenalidomidemonotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin","volume":"154","author":"Czuczman","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.03.001_bib40","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","article-title":"Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial","volume":"9","author":"Wang","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.03.001_bib41","first-page":"155","article-title":"Polatuzumabvedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"JClinOncol"},{"doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bartlett NL, Assouline S, et\u00a0al. Mosunetuzumab induces complete remissions in poor prognosis non-hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. ASH Annual Meeting Abstracts. San Diego, 2020.","key":"10.1016\/j.hoc.2020.03.001_bib42","DOI":"10.1182\/blood-2019-123742"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882030037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882030037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:14:16Z","timestamp":1760184856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985882030037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S088985882030037X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.03.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Histologic Transformation","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}